New report explores what's in store for Pharma and Biotech in 2018

The upward momentum seen in the pharma and biotech sectors during 2017 looks set to continue into 2018, with more novel medicines set to hit the market and investor support for the industry remaining strong.

According to EP Vantage, the editorial arm of Evaluate, the current business friendly stance at the US Food and Drug Administration is unlikely to change next year, while M&A could see an uptick, driven by big pharma and big biotech’s need to re-stock pipelines and US tax reforms.

The coming year will also test the commercial expectations that have been hung on novel therapies like CAR-T and gene therapy, which are being launched into increasingly cost-sensitive markets. Important clinical read-outs from the field of immuno-oncology, where asset values remain very high, will be closely watched - all of which will help set the tone for investors throughout the year.